Regenerative medicine · 2025
Effect of mesenchymal stem cell conditioned medium on hepatocyte matrix implant to alleviate liver cirrhosis in rats.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hendrawan Siufui, Lheman Jennifer, Dewi Fitriya Nur Annisa, Nuraeni, Permanawati, Baer Hans Ulrich
Аннотация
BACKGROUND: Hepatocyte transplantation has gained importance as an alternative treatment to orthotopic liver transplantation for end-stage liver disease. This study explores the modification of the hepatocyte matrix implant (HMI) procedure by replacing islet cells with conditioned medium (CM) derived from human umbilical cord-MSC (hUC-MSC) supplementation to alleviate liver cirrhosis in a rat model.
METHODS: The male Sprague Dawley rats were induced liver cirrhosis using thioacetamide for 11 weeks, and implanted with matrices on the small bowel mesentery, according to the groups. Four groups were assessed: blank matrix (cell-free), hepatocytes seeded-matrix (Hep), hepatocytes+islets co-seeded-matrix (Hep:Islet), and hepatocytes seeded-matrix supplemented with CM (Hep+CM).
RESULTS: In vitro, the Hep+CM group showed significantly higher hepatocyte proliferation than the Hep:Islet group, though albumin production was similar. The in vivo study further confirmed that the implanted hepatocytes remained viable and were able to produce albumin for at least 4 months post-implantation. Liver function parameters were shown to be improved in Hep:Islet and Hep+CM groups. Notably, collagen deposition in the liver was lower in Hep:Islet and Hep+CM groups compared to other groups.
CONCLUSION: These findings suggest that CM can effectively replace islet in supporting hepatocyte proliferation and function, enhancing the therapeutic potential of HMI procedure. No writing assistance was utilized in the production of this manuscript or liver cirrhosis treatment.
METHODS: The male Sprague Dawley rats were induced liver cirrhosis using thioacetamide for 11 weeks, and implanted with matrices on the small bowel mesentery, according to the groups. Four groups were assessed: blank matrix (cell-free), hepatocytes seeded-matrix (Hep), hepatocytes+islets co-seeded-matrix (Hep:Islet), and hepatocytes seeded-matrix supplemented with CM (Hep+CM).
RESULTS: In vitro, the Hep+CM group showed significantly higher hepatocyte proliferation than the Hep:Islet group, though albumin production was similar. The in vivo study further confirmed that the implanted hepatocytes remained viable and were able to produce albumin for at least 4 months post-implantation. Liver function parameters were shown to be improved in Hep:Islet and Hep+CM groups. Notably, collagen deposition in the liver was lower in Hep:Islet and Hep+CM groups compared to other groups.
CONCLUSION: These findings suggest that CM can effectively replace islet in supporting hepatocyte proliferation and function, enhancing the therapeutic potential of HMI procedure. No writing assistance was utilized in the production of this manuscript or liver cirrhosis treatment.